Bayer Aktiengesellschaft (FRA:BAYN)
Germany
· Delayed Price · Currency is EUR | Market Cap | 27.00B |
| Revenue (ttm) | 46.58B |
| Net Income (ttm) | -3.25B |
| Shares Out | n/a |
| EPS (ttm) | -3.32 |
| PE Ratio | n/a |
| Forward PE | 5.94 |
| Dividend | 0.11 (0.40%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 3,444,812 |
| Average Volume | 3,411,334 |
| Open | 27.26 |
| Previous Close | 27.82 |
| Day's Range | 27.13 - 27.49 |
| 52-Week Range | 18.38 - 31.03 |
| Beta | n/a |
| RSI | 74.47 |
| Earnings Date | Aug 6, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial StatementsNews
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer and the Broad Institute today announced that they have extended their research collaboration of 10 years by an additional five years, to further advan...
Bayer raised to Buy at Goldman after hitting bottom of negative earnings revision cycle
Bayer Crop Science delegation visits ISARC
Bayer Crop Science delegation visits ISARC : A four-member delegation from Bayer Crop Science visited the International Rice Research Institute - Sout.
Bayer subsidiary gains worldwide rights to develop cancer asset VVD-214
Bayer gets FDA nod for Nubeqa in advanced prostate cancer
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
SAN DIEGO & BERLIN, Germany--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, ...
Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that it will present multiple new analyses of the KERENDIA ® (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Con...
Bayer says new lung cancer therapy granted FDA priority review
Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea
European markets hold steady as traders await fresh cues; Bayer, Philips, SAP on the move
Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals
German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche'...
Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 clinical tr...
Bayer A.G.'s eye disease treatment gets approval in China
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI ...
Bayer Highlights New Data from Oncology and Women's Health Portfolios at 2025 ASCO Annual Meeting
WHIPPANY, N.J.--(BUSINESS WIRE)--The latest data from studies across Bayer's oncology and women's health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) ...
Bayer CEO on managing through the good and bad: Call out the problems
Bayer CEO Bill Anderson takes the stage at the 2025 CNBC CEO Council Summit to talk to leaders about managing through uncertainty and tackling problems head-on.
Dr. Yesmean Wahdan from Bayer Discusses Women's Health Month with YourUpdateTV
May is Women's Health Month – Dr. Yesmean Wahdan Shares Important and Timely Tips to Help Women Prioritize Their Health at Every Life Stage May is Women's Health Month – Dr. Yesmean Wahdan Shares Impo...
Fluor-Built Pharmaceutical Facility in California is First Industrial Manufacturing Facility in Western United States to Achieve LEED v4 Platinum Certification
Fluor Corporation (NYSE: FLR) announced today that Bayer’s Cell Therapy Launch Facility in Berkeley, California, has been designated the first industrial manufacturing facility in the Western United S...
Bayer Stock Investment Could Pay Off, But It Is Not For The Faint Of Heart
Bayer seeks Roundup settlement, explores Monsanto bankruptcy, WSJ reports
Bayer is seeking to resolve lawsuits related to its Roundup weedkiller, while exploring a bankruptcy for its Monsanto unit if the settlement plan fails, the Wall Street Journal reported on Thursday, c...
Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy
Bayer US head says FDA chief reassured pharma executives of timely reviews
Bayer Pharmaceuticals' chief operating officer said the head of the top U.S. drug regulator recently reassured industry executives that the Food and Drug Administration would meet its targets for revi...
Bayer exec: Trump pharma tariffs would negatively impact R&D
Tariffs on pharma products could hinder R&D efforts, says Bayer exec. Read more here
EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Euro...